Unlocking the true potential of Image Guided Ablation Therapy

Designed for Real time Predictive visualization of ablation tissue response

Ablation Tissue Response Visualized.

The innovative BioTrace Technology designed to predict and visualize the 24-hour post-treatment ablation tissue response in real-time

Allowing physicians to see where they have previously been blind

BioTrace™ is designed to interface with commercial ultrasound imaging systems. Its core innovation is in tracking the tissue’s unique “biological signature” when responding to heat during thermal ablation. This signature will be used to predict and visualize the post 24-hour thermal effect with the goal of optimizing the surgeon’s level of control and accuracy during the procedure, to minimize healthy tissue damage and maximize target tissue ablation.

A comprehensive all-around system

An A to Z Solution, the BioTrace™ technology is designed to affect and improve all stages of patient care, from PSM, through planning & simulation to real-time lesion imaging & efficacy analysis

 

 

Pre-interventional Patient Specific Modeling

Planning & Validation Of Manufacturers’ Protocols

Real-Time Visual Monitoring & Control Of Tissue Destruction

Real-Time Efficacy Analysis Of Post-Treatment Tissue Damage

The information on this website regarding the BioTrace technology is for demonstration purposes only. The BioTrace technology as presented in the website is limited by U.S. law to investigational use.

Providing vision. Aimed at Optimizing results.

A must have system for optimal ablation

Efficacy

Designed to maximize efficacy and technical success

Safety

Designed to avoid overtreatment and increase safety​

Cost

Designed to be cost effective. No hardware necessary

Ease of Use

Designed to seamlessly integrate to existing workflow ​

Clinical Study Case Examples

One real-time image is better than a thousand simulations

The provided cases performed in collaboration with Dr. Ryosuke Tateishi, University Tokyo Hospital

  • CASE 01

    • 61 Year-Old Patient
    • RFA Ablation
    • Tumor Size 1.8 cm
    • Liver Segment #3
    • Ablation time: 3 min

    92%

    BioTrace™ accuracy

    compared with 24h post CECT

    CASE 01

    92%

    BioTrace™ accuracy

    compared with 24h post CECT

  • CASE 02

    • 58 Year-old Patient
    • RFA Ablation
    • Tumor Size 2.2 cm
    • Liver Segment #6
    • Ablation time: 2.4min

    91% BioTrace™ accuracy

    compared with 24h post CECT

    CASE 02

    91% BioTrace™ accuracy

    compared with 24h post CECT

  • CASE 03

    • 63 Year-old Patient
    • MW Ablation
    • Tumor Size 1.5 cm
    • Liver segment #4
    • Ablation time: 2min

    90% BioTrace™ accuracy

    compared with 24h post CECT

    CASE 03

    90% BioTrace™ accuracy

    compared with 24h post CECT

Transforming ablation treatments into guided precision therapies

Current Application

Oncology
Liver tumor ablation

Advancing thermal ablation into the first line treatment option for tumor removal

Pipeline

Cardiovascular

Transitioning from complicated guess-work into precise, real-time feedback dependent treatments

Pain management

Dramatically increase safety in high-risk nerve-ablation procedures

Team

Yossi Abu CEO

Tal Sitbon COO

Bob GerberichCCO &
Head of N. America
TOM EDLUND CTO

Limor ALtholTzCFO
Eran Naveh Chief Strategy Officer
Tobias Preusser GM TCSM GmbH
Dubi Finklshtein VP Sales
Yogev Zohar VP Product
Talia Goshen Deputy General Manger
Nitzan Even BizDev & Marketing Director

Board of Directors

Chairman of the Board

MR. ARIE ROSENFELD

Former President & CEO, Scitex Corp

Director 

MR. YOSSI ABU

Founder & CEO, TechsoMed

Director 

MR. EIJI KAKIUICHI

Chairman, SCREEN Holdings

Director

MR. TODD KALOUDIS

Managing Director, Cobro Ventures

Director 

MR. FRED SHANE

Managing Partner, Axil Capital

Director 

MR. WANG CHONG

Executive Director, Yonghua Capital

Partnerships

Investors

Partners

Clinical

News

January 2024

Techsomed BioTrace Solution Achieves De Novo Clearance From FDA as the First Ultrasound-Based Software for Tissue Response Prediction in Liver Tumor Ablation

September 2023

Techsomed Announces FDA Clearance for Ablation Treatment Planning and Confirmation Software

 

December 2022

User-Friendly, complete system for more targeted, effective thermal ablation treatment 

 

June 2023

Field Evaluation  of BioTrace.IO 360 using GE HealthCare’s Logiq™ ultrasound systems at top USA clinical sites

December  2022

TechsoMed announces the opening of a new subsidiary in Bremen with Fraunhofer Mevis to accelerate End-to-End solutions for Image-Guided Thermal Ablation therapy

 

October 2022

TechsoMed announces completion of full enrollment in pivotal US trial, evaluating its BioTraceIO software for liver ablation outcomes assessment in liver cancer patients

 

February 2022

The Japanese subsidiary of TechsoMed expands its business

April 2021

Biotrace allows doctors to see the impossible

 

April 2021

With Lenovo, TechsoMed is spurring a revolution in cancer treatment

April 2021

TechsoMed raises $7 Millionseries B financing led by Axil capital      

Contact Us

To contact Techsomed’s support team send an Email to: support@techsomed.com

Contact info

TechsoMed
Tel:  +972-8-6198866
Email:  info@techsomed.com
Meir Weisgal 2, Rehovot, Israel

The information on this website regarding the BioTrace technology is for demonstration purposes only.

The BioTrace technology as presented in the website is limited by U.S. law to investigational use. 

MK000014-001